Results 141 to 150 of about 3,014 (182)
Erdafitinib Versus Pembrolizumab in Pretreated Patients With Advanced or Metastatic Urothelial Cancer With Select FGFR Alterations: Cohort 2 of the Randomized Phase III THOR Trial☆ [PDF]
Annals of OncologyBackground: Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFRalt) who progressed ...
Peter Schatteman +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine, 2023Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 alterations who have progression after platinum-containing chemotherapy. The effects of erdafitinib in patients with FGFR-altered metastatic urothelial carcinoma who
Severine Banek +2 more
exaly +4 more sources
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
ONCOLOGY, 2023A Hispanic man, aged 42 years, was diagnosed with stage IV metastatic urothelial bladder cancer (MUBC) with nonregional lymphadenopathies and lung, bone, and skin involvement. He received first-line treatment with gemcitabine and cisplatin for 6 cycles, achieving a partial response (PR).
Francisco Javier, Castro-Alonso +4 more
openaire +2 more sources
New and convergent synthesis of erdafitinib
Journal of Heterocyclic Chemistry, 2022AbstractA new and convergent synthetic route of erdafitinib on a 20 g scale has been developed, from the commercially available chemicals quinoxalin‐2‐ol, 4‐bromo‐1‐methyl‐1H‐pyrazole, and 2‐bromo‐1,1‐dimethoxyethane. The key intermediate 3,5‐dimethoxyphenyl‐isopropylethane‐1,2‐diamine (17) was prepared from 2‐bromo‐1,1‐dimethoxyethane in 89% yield ...
Zhiyong Xu +4 more
openaire +1 more source
Erdafitinib for the Treatment of Urothelial Cancer
Expert Review of Anticancer Therapy, 2019Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in luminal-1 UC subtype, which exhibits poor responses to immunotherapy. Erdafitinib is a potent and selective pan-FGFR tyrosine kinase inhibitor.
Laura Marandino +2 more
exaly +3 more sources
Erdafitinib for the treatment of metastatic bladder cancer
Expert Review of Clinical Pharmacology, 2019Introduction: Since the approval of immune checkpoint inhibitors (ICIs), there has been continuing and significant progress in urothelial cancer (UC) treatment. However, only about one fifth of UC patients respond to ICI. Recently, erdafitinib was developed for treating locally advanced or metastatic UC (mUC) with FGFR3 or FGFR2 alterations, accounting
Kamaneh, Montazeri, Joaquim, Bellmunt
openaire +2 more sources
Erdafitinib: First Global Approval
Drugs, 2019Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers including cholangiocarcinoma, liver ...
openaire +2 more sources
Erdafitinib to treat urothelial carcinoma
Drugs of Today, 2019Erdafitinib is the first Food and Drug Administration (FDA)-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to four FGFRs (FGFR-1 to -4), leading to decreased cell signaling and cellular apoptosis. Erdafitinib also binds to RET, colony-stimulating factor 1 receptor (CSF-1R), platelet-derived growth factor receptor
openaire +2 more sources